Research Only Immune & Anti-Inflammatory

hBD-1

also known as: human β-defensin 1, DEFB1, defensin β1, hBD1

The constitutive epithelial β-defensin — first isolated from haemodialysate urine by Bensch, Schröder and colleagues (FEBS Letters 1995). Constitutively expressed (unlike hBD-2 and hBD-3, which are inducible), salt-sensitive in standard assays, and a major component of urogenital and airway surface antimicrobial defense.

A 36-amino-acid cationic β-defensin with the β-defensin-class three-disulfide fold (Cys1-Cys5, Cys2-Cys4, Cys3-Cys6; distinct connectivity from α-defensins). First isolated from the haemodialysate of patients with chronic renal failure (Bensch, Schnebli, Schulz-Knappe, Schröder et al., FEBS Lett, 1995). Expressed constitutively by epithelial cells lining the urogenital tract, kidney tubules, airways, gingiva and skin; basal expression is not meaningfully inducible by pro-inflammatory cytokines (distinguishing it from hBD-2 and hBD-3). Its activity in vitro is notably salt-sensitive — microbicidal potency falls sharply at physiological NaCl concentrations — which has driven long-running debate about its in-vivo contribution and a hypothesis that disulfide-reduced hBD-1 in the gut has much broader activity than the oxidised form.

Mechanism of action

Classical defensin-class mechanism: cationic binding to anionic microbial membranes followed by membrane permeabilisation. Microbicidal spectrum in vitro includes E. coli, Pseudomonas, K. pneumoniae and C. albicans, with weaker Gram-positive activity in the standard oxidised form. A 2011 paper (Schroeder, Wu, Stange, Wehkamp et al., Nature) showed that disulfide-reduced hBD-1 has dramatically broader and more potent activity against anaerobic Gram-positive commensals including bifidobacteria — pointing to a role in shaping mucosal microbiota rather than simply killing invaders. Beyond microbicidal activity, hBD-1 acts as a chemokine for CCR6-expressing immature dendritic cells and memory T cells, linking innate barrier function to adaptive immunity.

Primary uses

  • Research reagent for antimicrobial peptide and mucosal immunity studies
  • Epithelial biology and barrier research
  • Microbiome research on defensin-microbiota interactions
  • Clinical biomarker research (salivary, airway, urinary hBD-1 in infection and periodontitis)

Typical dosing

Not established

⚠ No human dosing established. hBD-1 has never been administered as a therapeutic.

Regulatory status

Not a drug. hBD-1 is an endogenous epithelial antimicrobial peptide studied as a research reagent. No β-defensin has been developed as an approved therapeutic, though hBD-1 / hBD-2 / hBD-3 concentrations in saliva, sputum and urine have been studied as biomarkers of infection and inflammation.

References

  1. [pubmed] Bensch KW, Raida M, Mägert HJ, Schulz-Knappe P, Forssmann WG. "hBD-1: a novel beta-defensin from human plasma." FEBS Lett, 1995;368(2):331-335. (First isolation of hBD-1.)
  2. [pubmed] Schroeder BO, Wu Z, Nuding S, et al. "Reduction of disulphide bonds unmasks potent antimicrobial activity of human β-defensin 1." Nature, 2011;469(7330):419-423.
  3. [review] Ganz T. "Defensins: antimicrobial peptides of innate immunity." Nat Rev Immunol, 2003;3(9):710-720.

Related peptides

hBD-2

The inducible β-defensin — cloned by Harder, Bartels, Christophers and Schröder (Nature 1997) from the lesional scales of psoriasis patients, with the paper framing psoriatic skin as a paradoxical "almost-never-infected" phenotype driven by massive β-defensin induction. Induced by TLR / NF-κB signalling in response to bacterial lipopolysaccharide and pro-inflammatory cytokines (IL-1, TNF-α).

hBD-3

The broad-spectrum β-defensin — active against Gram-positive, Gram-negative and fungal targets, and largely salt-insensitive (unlike hBD-1). Isolated independently in 2001 by Harder et al. and by García et al. from psoriatic skin and tonsil respectively. The β-defensin most studied for clinical translation because of its salt tolerance.

HNP-1

The prototype human α-defensin — isolated from neutrophil granules by Ganz, Selsted and Lehrer in 1985; the dominant antimicrobial peptide in human neutrophils and a workhorse molecule of innate immunity. Research peptide only: no defensin has ever been developed as an approved drug.

HD5

The Paneth cell α-defensin — the dominant antimicrobial peptide of the human small intestine, stored at millimolar concentrations in Paneth cell secretory granules and released into the crypt lumen upon cholinergic or bacterial stimulus. Reduced HD5 expression is a recognised feature of ileal Crohn disease.

HD6

The Paneth cell α-defensin that does not kill directly — HD6 traps enteric pathogens by self-assembling into fibrillar "nanonets" (Chu et al., Science 2012), a mechanism unique among the defensin family. Poor microbicidal activity in vitro was a decade-long puzzle until the trapping mechanism was discovered.
Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.